Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hyp...
Saved in:
Main Authors: | Stephen Melnick (Author), Priya Rajagopalan (Author), Theresa Lynn (Author), Anthony Donato (Author) |
---|---|
Format: | Book |
Published: |
Greater Baltimore Medical Center,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
by: Navya Varshney, et al.
Published: (2021) -
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
by: Nunzia D'Onofrio, et al.
Published: (2021) -
Sodium-glucose co-transporter 2 inhibitors - a review article
by: Marcin Makuch, et al.
Published: (2019) -
Sodium-glucose co-transporter 2 inhibitors - a review article
by: Marcin Makuch, et al.
Published: (2019) -
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
by: Yuling Jing, et al.
Published: (2022)